Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution.

Jimenez-Zepeda VH, Duggan P, Neri P, Chaudhry A, Tay J, Bahlis N.

Leuk Lymphoma. 2017 Nov 21:1-7. doi: 10.1080/10428194.2017.1403026. [Epub ahead of print]

PMID:
29160734
2.

Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience.

Lee H, Duggan P, Chaudhry A, Neri P, Tay J, Rashid-Kolvear F, Bahlis NJ, Jimenez-Zepeda VH.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e69-e75. doi: 10.1016/j.clml.2017.10.009. Epub 2017 Nov 1.

PMID:
29158114
3.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C.

Blood. 2018 Jan 18;131(3):301-310. doi: 10.1182/blood-2017-07-795047. Epub 2017 Nov 17.

4.

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG.

Blood. 2017 Dec 14;130(24):2610-2618. doi: 10.1182/blood-2017-06-791228. Epub 2017 Oct 20.

PMID:
29054911
5.

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.

Moreau P, Dimopoulos MA, Richardson PG, Siegel DS, Cavo M, Corradini P, Weisel K, Delforge M, O'Gorman P, Song K, Chen C, Bahlis N, Oriol A, Hansson M, Kaiser M, Anttila P, Raymakers R, Joao C, Cook G, Sternas L, Biyukov T, Slaughter A, Hong K, Herring J, Yu X, Zaki M, San-Miguel J.

Eur J Haematol. 2017 Sep;99(3):199-206. doi: 10.1111/ejh.12903. Epub 2017 Jun 14.

PMID:
28504846
6.

Multiple myeloma cells sent "PAKing"!

Neri P, Bahlis NJ.

Blood. 2017 Apr 20;129(16):2208-2209. doi: 10.1182/blood-2017-02-764662. No abstract available.

PMID:
28428234
7.

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.

Bahlis NJ, Corso A, Mugge LO, Shen ZX, Desjardins P, Stoppa AM, Decaux O, de Revel T, Granell M, Marit G, Nahi H, Demuynck H, Huang SY, Basu S, Guthrie TH, Ervin-Haynes A, Marek J, Chen G, Facon T.

Leukemia. 2017 Nov;31(11):2435-2442. doi: 10.1038/leu.2017.111. Epub 2017 Apr 4.

8.

Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?

Lee H, Duggan P, Neri P, Tay J, Bahlis NJ, Jimenez-Zepeda VH.

Bone Marrow Transplant. 2017 Jun;52(6):915-917. doi: 10.1038/bmt.2017.28. Epub 2017 Mar 13. No abstract available.

PMID:
28287637
9.

Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.

Jimenez-Zepeda VH, Duggan P, Neri P, Tay J, Bahlis NJ.

Ann Hematol. 2017 Mar;96(3):431-439. doi: 10.1007/s00277-016-2901-x. Epub 2017 Jan 10.

PMID:
28074255
10.

New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.

Neri P, Bahlis NJ, Lonial S.

Clin Cancer Res. 2016 Dec 15;22(24):5959-5965. Epub 2016 Oct 19. Review.

11.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators.

N Engl J Med. 2016 Oct 6;375(14):1319-1331.

12.

Treatment of Relapsed/Refractory Multiple Myeloma.

Neri P, Bahlis NJ, Paba-Prada C, Richardson P.

Cancer Treat Res. 2016;169:169-194. Review.

PMID:
27696263
13.

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation.

Shah SP, Nooka AK, Jaye DL, Bahlis NJ, Lonial S, Boise LH.

Oncotarget. 2016 Sep 13;7(37):59727-59741. doi: 10.18632/oncotarget.10847.

14.

Revised International Staging System Applied to Real World Multiple Myeloma Patients.

Jimenez-Zepeda VH, Duggan P, Neri P, Rashid-Kolvear F, Tay J, Bahlis NJ.

Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):511-518. doi: 10.1016/j.clml.2016.06.001. Epub 2016 Jun 8.

PMID:
27425179
15.

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.

Han M, Murugesan A, Bahlis NJ, Song K, White D, Chen C, Seftel MD, Howsen-Jan K, Reece D, Stewart K, Xie Y, Hay AE, Shepherd L, Djurfeldt M, Zhu L, Meyer RM, Chen BE, Reiman T.

Blood. 2016 Aug 4;128(5):732-5. doi: 10.1182/blood-2016-06-716902. Epub 2016 Jun 23. No abstract available.

16.

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H.

Blood. 2016 Jul 7;128(1):37-44. doi: 10.1182/blood-2016-03-705210. Epub 2016 May 23.

17.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group.

N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.

18.

MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.

Shah MY, Martinez-Garcia E, Phillip JM, Chambliss AB, Popovic R, Ezponda T, Small EC, Will C, Phillip MP, Neri P, Bahlis NJ, Wirtz D, Licht JD.

Oncogene. 2016 Nov 10;35(45):5905-5915. doi: 10.1038/onc.2016.116. Epub 2016 Apr 25.

PMID:
27109101
19.

Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.

Jimenez-Zepeda VH, Duggan P, Neri P, Bahlis NJ.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e79-84. doi: 10.1016/j.clml.2016.03.005. Epub 2016 Mar 29.

PMID:
27101985
20.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM.

Lancet. 2016 Apr 9;387(10027):1551-60. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.

PMID:
26778538

Supplemental Content

Loading ...
Support Center